MedTrace Logo

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06030076 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-01-29

No results posted yet for this study

Summary

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.

Conditions

Interventions

DRUG

Tildrakizumab

As provided in real-world clinical practice.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-06
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030076 on ClinicalTrials.gov